Consequently, two small molecule inhibitors targeting EGFR, gefitinib (Iressa®, 2003), and erlotinib (Tarceva®, 2004) received FDA approval as treatment for NSCLC patients who had failed chemotherapy [15]. Here, EGFR is linked to non-small cell lung carcinoma.